What is Leerink Partnrs’ Forecast for PRCT FY2029 Earnings?

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – Equities researchers at Leerink Partnrs issued their FY2029 EPS estimates for PROCEPT BioRobotics in a research report issued to clients and investors on Tuesday, February 25th. Leerink Partnrs analyst M. Kratky anticipates that the company will post earnings per share of $0.48 for the year. The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share.

Other equities research analysts have also issued reports about the stock. Morgan Stanley dropped their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research report on Wednesday. Wells Fargo & Company restated an “overweight” rating and issued a $112.00 price objective on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Truist Financial restated a “buy” rating and set a $90.00 price target (down from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday. Finally, Jefferies Financial Group assumed coverage on shares of PROCEPT BioRobotics in a research note on Thursday, November 14th. They set a “hold” rating and a $95.00 price objective for the company. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, PROCEPT BioRobotics presently has an average rating of “Moderate Buy” and an average price target of $94.29.

PROCEPT BioRobotics Stock Performance

NASDAQ:PRCT opened at $65.02 on Thursday. PROCEPT BioRobotics has a twelve month low of $45.20 and a twelve month high of $103.81. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The stock has a market cap of $3.39 billion, a P/E ratio of -33.34 and a beta of 1.03. The business’s 50-day moving average price is $75.25 and its two-hundred day moving average price is $79.94.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The firm had revenue of $68.24 million during the quarter, compared to analysts’ expectations of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, EVP Alaleh Nouri sold 28,092 shares of PROCEPT BioRobotics stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the completion of the transaction, the executive vice president now directly owns 52,472 shares in the company, valued at approximately $5,096,605.36. This trade represents a 34.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Reza Zadno sold 26,423 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $97.22, for a total value of $2,568,844.06. Following the completion of the sale, the chief executive officer now owns 152,762 shares in the company, valued at $14,851,521.64. The trade was a 14.75 % decrease in their position. The disclosure for this sale can be found here. Insiders own 17.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Westfield Capital Management Co. LP purchased a new stake in shares of PROCEPT BioRobotics during the third quarter valued at approximately $72,563,000. FMR LLC lifted its holdings in shares of PROCEPT BioRobotics by 11.9% during the 4th quarter. FMR LLC now owns 8,159,208 shares of the company’s stock valued at $656,979,000 after buying an additional 866,328 shares during the period. Perpetual Ltd purchased a new position in shares of PROCEPT BioRobotics in the 4th quarter worth $66,972,000. Wellington Management Group LLP grew its holdings in shares of PROCEPT BioRobotics by 38.8% in the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company’s stock worth $120,051,000 after acquiring an additional 416,819 shares during the period. Finally, Franklin Resources Inc. increased its position in PROCEPT BioRobotics by 64.5% during the third quarter. Franklin Resources Inc. now owns 885,992 shares of the company’s stock valued at $64,669,000 after acquiring an additional 347,330 shares during the last quarter. Hedge funds and other institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).